

Oncology Clinical Trials - Current As Of October 2025

TUMOUR	TRIAL	Line	KEY POINTS - TRIAL/AGENT	PI	SC
Breast	OPTIMA	Adj	Optimal personalised treatment of early breast cancer using multi-parameter analysis, an international randomized trial of tumor gene expression test-directed chemotherapy treatment in a largely node-positive population	MW	JG
Breast	INAVO	1 st	A ph III study evaluating Inavolisib in combo with Phesgo vs placebo in combi with phesgo as maintenance therapy after 1st line induction tx in pts w PIK3CA mutated HER2 positive locally advanced or metastatic breast cancer	MW	JG
Breast	CAMBRIA-2	Adj	A Ph III, study to assess Camizestrant (AZD9833) vs Standard Endocrine Therapy for pts With ER+/HER2- Early Breast Cancer and an Intermediate-High/High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease	AM	RC
Breast	OLIO	Neoadj.	A ph II, randomised, non-comparative two-arm trial of neoadjuvant chemo plus either olaparib or olaparib + durvalumab in young, pre-menopausal women with HRD-enriched, HR-positive, HER2-negative early breast cancer	AM	RC
Breast	MONITOR HER2	N/A	Frequency of Cardiac Monitoring in Patients Treated with HER2-Directed Therapies for Breast Cancer	DD	JG
Breast	CECI830A12101	2 nd	Ph I/II study of ECI830 as a single agent and in combination with ribociclib and endocrine therapy in patients with advanced hormone receptor positive, HER2-negative breast cancer and advanced solid tumors	MW	JG
Breast	DESTINY BREAST 15	2 nd	Ph 3b, Multicenter, Global, Interventional, Open-label Study of T-DXd, an Anti-HER2-ADC, in Subjects who Have Unresectable and/or Metastatic HER2-low or HER2 IHC 0 Breast Cancer	MW	JG
Breast	OPERA-01	2nd +	Ph 3 study of OP-1250 monotherapy VS SOC for the tx of ER+, HER2- advanced or metastatic breast cancer following endocrine and CDK 4/6 inhibitor therapy	DD	RC
Breast	Ascent-05	1st	A Ph 3 study of adjuvant sacituzumab govitecan and pembrolizumab vs treatment of physician's choice in patients with TNBC who have residual invasive disease after surgery and neoadjuvant therapy	MW	JG
Breast	STML-ELA-0422	Adj	Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence—A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT)	MW	JG
Breast	CLEE011O12001	Adj	A phase IIIB study to characterize the efficacy and safety of Adjuvant ribociclib plus endocrine therapy in a close-to-clinical practice patient population with HR+ HER2- early breast cancer (Adjuvant WIDER)	MW	JG
All tumour types	KN-587	Any	Ph 3, Long term safety and efficacy in patients currently on treatment or followup from a Pembrolizumab trial	DL	KB
Biliary Tract	DESTINY-Biliary-01	1 st	Ph 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig vs Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer	ZW	JP
Solid Tumours	HERTHENA	2 nd +	A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Subjects with Locally Advanced or Metastatic Solid Tumors	SF	SH
Solid Tumours	Genescreen	Any	GeneScreen 5-FU: DPYD Genotype-guided dose Personalisation for Fluoropyrimidine prescribing in Solid Organ Cancer Patients	ZW	MS
Unknown primary	SUPER-ED	NA	Solving Unknown Primary cancer Earlier Diagnosis (SUPER-ED): A stepped wedge cluster randomised controlled trial implementing a Model of Care to support earlier diagnosis	ZW	KB
Pancreas	NEOFOL-R	1 st	Efficacy of Neoadjuvant FOLFIRINOX in Resectable pancreatic cancer: An international multicenter Randomized, controlled trial	DL	MS
Biliary Tract	BIL-PPP	2 nd +	Phase II study of the combination of durvalumab (MEDI4736) (PDL1 inhibitor) and olaparib (PARP inhibitor) in advanced cholangiocarcinoma after initial chemotherapy and durvalumab (BIL-PPP)	DL	SH
GOJ	Destiny gastric 05	1 st	A Multicenter, Randomized, Open-Label, Phase 3 Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab versus Chemotherapy Plus Trastuzumab Plus or Minus Pembrolizumab as First-line Treatment in Participants with Unresectable, Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction (GEJ) Cancer (DESTINY-Gastric05)	DL	MS
Prostate	AMG 509	3 rd	Ph I, AMG 509 in Subjects with Metastatic Castration-resistant Prostate Cancer	HH	LD
Prostate	MK5684-004	2 nd +	Ph 3, Randomized, Open-label Study of MK-5684 vs Alternative Abiraterone Acetate or Enzalutamide in pts w mCRPC That Progressed On or After Prior Treatment with One Nextgeneration Hormonal Agent (NHA)	HH	SM
Prostate	GO44537	2 nd +	Ph I, Open-Label, Multicenter, Dose-Escalation And Expansion Study Evaluating The Safety, Pharmacokinetics, And Activity Of RO7656594 In pts w Advanced Or Metastatic Prostate Cancer	EL	LD
Prostate	MEVPRO-1 C2321014	2 nd +	A Ph 3, Randomized, Open-Label Study Of PF-06821497 (Mevrometostat) In Combo With Enzalutamide Compared With Enzalutamide Or Docetaxel In Participants With Metastatic Castration Resistant Prostate Cancer Previously Treated With Abiraterone Acetate	HH	EQ
Prostate	20230005	2 nd +	A Ph 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in pts w Metastatic Castration-Resistant Prostate Cancer Previously Treated With Chemotherapy	HH	SW
Prostate	CJSB462C12201	1 st	A Phase II, randomized, open-label, multi-center study of JSB462 (luxdegalutamide) in combination with abiraterone in adult male patients with metastatic hormone-sensitive prostate cancer (mHSPC)	HH	HG
Endocrinology	I-FIRST	Any	A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients with RAIr Thyroid Cancer (I-FIRST study)	MM	LD
HNSCC	GS-US-699-7184	2 nd +	A Phase 2 Platform Study of Novel Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma	MA	EQ
Neuro	LUMOS2	2 ND	Phase 2, multi-centre, open-label, biomarker-directed, umbrella, clinical trial for recurrent IDH mutant, grade 2/3 glioma.	EA	SL

Breast
 Gastrointestinal (GI)
 Lung
 Genitourinary (GU)
 Gynaecology
 Head & Neck
 Skin
 Neuro
 PH 1

TUMOUR	TRIAL	Line	KEY POINTS - TRIAL/AGENT	PI	SC
NSCLC	SAFFRON	2 nd	Phase III study in EGFR mutated, MET Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer who have Progressed Following Treatment with Osimertinib	SA	HS
NSCLC	OCEANic	Adjuvant	Phase II, Open-label, Multi-centre Clinical Trial of Osimertinib With or Without Adjuvant Chemotherapy Guided by Tumour NGS Co-mutation Status and ctDNA Detection in Patients With Stage IIA-IIIa EGFR-Mutant NSCLC Following Complete Surgical Resection	SA	BN
NSCLC	eVOLVE lung 02	1 st	Ph III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine Efficacy of Volrustomig (MEDI5752) + Chemo vs Pembrolizumab + chemo for First-Line Treatment of pts with mNSCLC	SA	BN
NSCLC	MK-2870-004	3 rd	A Randomized, Open-label, Ph 3 Study of MK-2870 vs Chemotherapy (Docetaxel or Pemetrexed) in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) with EGFR Mutations or Other Genomic Alterations	SA	BN
NSCLC	Tropion-10	1 ^s	Ph III Study of Dato-DXd in Combo w AZD2936 or AZD2936 Monotherapy vs Pembro Monotherapy for First-line tx of Pts w Locally-advanced or Metastatic Non-squamous NSCLC With High PD-L1 Expression and Without Actionable Genomic Alterations	SA	BN
NSCLC	Tropion-14	1 st	Ph III Study of Osimertinib With or Without Dato-DXd as First-line Treatment in Participants w/ EGFR Mutation-positive, Locally Advanced or Metastatic NSCLC	SA	HS
Meso	eVOLVE meso	1 st	Ph III, Randomized, Study of Volrustomig (MEDI5752) in Combo w Carboplatin plus Pemetrexed vs Platinum plus Pemetrexed or Nivolumab plus Ipilimumab in pts with Unresectable Pleural Mesothelioma	SA	AF
SCLC	DeLLphi- 306	Adjuvant	A Phase 3, Randomized, double-blind, placebo-controlled, multicentre study of Tarlatamab Therapy in subjects with limited stage small cell lung cancer (LS-SCLC) who have not progressed following concurrent chemoradiation therapy.	SA	BN
SCLC	DeLLphi-309	2 nd	A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects with SCLC	SA	ZF
SCLC	Dellphi-312	1 st	A Phase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in combination with Durvalumab, Carboplatin and Etoposide versus Durvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer (DeLLphi-312)	SA	AF
Endometrial	ADELE	Adjuvant	Ph 2 Adjuvant tislezumab plus chemotherapy after post-operative pelvic chemoradiation in high risk Endometrial cancer	KW	DG
Endometrial	XPORT-EC-042	2 nd +	Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma	KW	HT
Gynaecological Neoplasms	PARAGON II	1 st +	Phase II basket study of an aromatase inhibitor plus PI3KCA inhibitor or CDK4/6 inhibitor in women with hormone receptor positive recurrent/metastatic gynaecological neoplasms	KW	ED
Gynaecological Neoplasms	GLORIOSA	2 nd +	Ph 3 study of mirvetuximab soravtansine in combo with bevacizumab vs bevacizumab alone as maintenance therapy for pts with FRα-high recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab	GH	ED
Ovarian	EPOCH	2 nd +	Catalina-2: A Phase 2 Study Evaluating The Efficacy And Safety Of TORL-1-23 In Women With Advanced Platinum-Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal And Fallopian Tube Cancers) Expressing Claudin 6	GH	DS
Cervical	TroFuse	2 nd +	A Ph 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare MK-2870 Monotherapy vs Treatment of Physician's Choice as Second-line Treatment for pts w Recurrent or Metastatic Cervical Cancer	SF	DG
Ovarian	IMGN853-0425	2 nd +	A randomized Phase 2, open-label study of mirvetuximab soravtansine in patients with platinum-resistant advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression testing 2 schedules of administration for dose optimization, with a separate cohort to determine starting dose in patients with moderate hepatic impairment	KW	ED
Endometrial	ASCENT-GYN-01	2 nd +	Ph 3 Study of Sacituzumab Govitecan vs tx of Physician's Choice in Participants w Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy	KW	DS
Solid tumours	DB-1303-O-1001	2 nd +	A Ph 1/2a, Multicenter, Open-Label, FIH Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1303/BNT323 in Patients with Advanced/Metastatic Solid Tumors	SF	HT
Gynaecological Neoplasms	IMGN151-1001	2 nd +	A Phase 1, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (anti-FRα antibody-drug conjugate) in Adult Patients with Recurrent Gynaecological Cancers	KW	DG

Breast
 Gastrointestinal (GI)
 Lung
 Genitourinary (GU)
 Gynaecology
 Head & Neck
 Skin
 Neuro
 PH 1

TUMOUR	TRIAL	Line	KEY POINTS - TRIAL/AGENT	PI	SC
Solid Tumour	SR854A-001	2 nd +	Phase 1, Dose Escalation, Safety, Tolerability, and Pharmacokinetic Study of SR-8541A (ENPP1 inhibitor) Administered Orally as Monotherapy in Subjects with Advanced/Metastatic Solid Tumors	AB	LS
Solid Tumour	EOHC-1001-101	2 nd +	Ph1, dose escalation of EO1001 (oral pan-ErbB inhibitor) in patients with Advanced solid tumours positive for EGFR, HER2 or HER4.	SF	PM
Solid Tumour	VT3989-001 - Vivace	2 nd +	Phase I/II, Multi-Center, Open-Label Study of VT3989, Alone or in Combination, in pts with Locally Advanced or Metastatic Solid Tumors	AB	PM
Solid Tumour	CP-AU-007-01	2 nd +	Ph 1 first in human dose escalation of AU-007 monoclonal antibody to IL2 in advanced solid tumours	SF	OC
Solid Tumour	MK-1084	2 nd +	Ph 1, MK-1084 (KRAS G12C inhibitor) as monotherapy in advanced solid tumours or in combination with pembrolizumab (NSCLC)	EA	HA
Solid Tumour	AXA-042-FIH-01	2 nd +	Ph1, A Phase 1a/1b, first-in-human, open-label, non-randomized, multicenter, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of AXA-042 as monotherapy and in combination with checkpoint inhibitors in subjects with advanced solid tumours.	SF	HA
Solid Tumour	Genentech GO43860	2 nd +	A Phase 1a/1b open label, multicentre, dose-escalation study to evaluate the safety, pharmacokinetics, and activity of RO7502175 as a single agent and in combination with atezolizumab in patients with locally advanced or metastatic solid tumours	SF	HA
Solid Tumour	HM-EZHI-101	2 nd +	A Phase I, Open-Label, Multicenter, Dose Escalation and Expansion Study of HM97662 as a Single Agent in Patients With Advanced or Metastatic Solid Tumours	AB	KD
Solid Tumour	GS-US-570-6015	2 nd +	Phase 1 study of GS-1811 as monotherapy and in combination with a checkpoint inhibitor in patients with advanced solid tumours	DD	PM
Solid Tumour	IOS-1002-201	2 nd +	Ph 1a/1b, FIH, open-label, non-randomized, multicenter, dose-escalation and cohort expansion study to IOS-1002 administered alone and in combo with a PD-1 monoclonal antibody in advanced solid tumors	EA	LM
Solid Tumour	AWT020	2 nd +	Ph 1/2, FIH, Open-label Study of Single-agent AWT020 in pts w Progressive Locally Advanced or Metastatic Cancer	SF	LS
Solid Tumour	DCSZ11-101	2 nd +	Ph 1, Multicenter, Open-Label, Dose Escalation, and Dose Expansion Study to DCSZ11 as a Monotherapy and in Combo in pts with Advanced or Metastatic Solid Tumors	DD	HA
Solid Tumour	BG-68501-101	2 nd +	A Phase 1a/1b Study of BG-68501 a Selective CDK2 Inhibitor, in Participants With Advanced Solid Tumors	DD	LS
Solid Tumour	BG-C9074-101	2 nd +	Ph 1a/1b Study of BG-C9074, an ADC Targeting B7H4, as Monotherapy and in combo w/ Tislelizumab in pts With Advanced Solid Tumors	AB	OC
Solid Tumour	PMV-586-101	2 nd +	A Ph 1/2 Open-label, Multicenter Study to Assess PC14586 in pts w/ Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation	AB	KD
Solid Tumour	PRT7732-01	2 nd +	A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT7732, an Oral SMARCA2 Degradar, in Patients with Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation	AB	LM
Solid Tumour	DM001001	2 nd +	A Phase I, Multicenter, Open-label, FIH, Dose Escalation and Expansion Study of DM001 in Patients with Advanced Solid Tumors	SF	OC
Solid Tumour	YL211-INT-101-01	2 nd +	A Phase 1, Multicenter, Open-Label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients with Advanced Solid Tumors	SF	OC
Solid Tumour	BGB-53038-101	2 nd +	A Ph 1a/1b Study to Investigate BGB-53038, a Pan-KRAS Inhibitor, as Monotherapy or in Combo in Patients With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification	SF	HA
Solid Tumour	BG-C137-101	2 nd +	A Phase 1a/b, Open-label, Multicenter Study to Investigate BG-C137, an Antibody-Drug Conjugate Targeting FGFR2b, in Patients With Advanced Solid Tumors	AB	LM
Solid Tumour	PAUF-I	2 nd +	A FIH, Phase 1/2a, Multicentre, Open-label Study Evaluating PBP1510 in Patients with Advanced/Metastatic Pancreatic Cancer	AB	PM
Solid Tumour	BGB-58067-101	2 nd +	A Ph 1a/b Study Investigating BGB-58067, an MTA-Cooperative PRMT5 Inhibitor in Patients With Advanced Solid Tumors	EA	LM
Solid Tumour	CP-IVX037	2 nd +	A ph 1 study of intratumoral IVX037 as monotherapy or in combo w an immune checkpoint inhibitor in pts w advanced/metastatic solid tumors	SF	LM
Solid Tumour	BNT317	2 nd +	Ph I, FIH, open-label, dose escalation study of BNT317 in pts w advanced solid tumors	SF	PM
Solid Tumour	CS2009-101	2 nd +	Ph I, Dose-Escalation and Dose-Expansion Study to Evaluate CS2009, a tri-specific antibody targeting PD-1/VEGFA/CTLA-4, in Participants with Advanced Solid Tumors	SF	PM
Solid Tumour	BM230-01	2 nd +	Ph I, Multicenter, Non-randomized, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BM230 in Patients with Advanced Solid Tumors	EA	LS
Solid Tumour	SNV1521-101	2 nd +	Ph I, open-label dose escalation and expansion study of SNV1521 in pts with advanced solid tumors	SF	LS
Solid Tumour	SNV4818-101	2 nd +	Ph I, Open-Label Dose Escalation and Expansion Study of SNV4818 as Monotherapy or in combo w other Anticancer Agents in pts with Advanced Solid Tumors.	SF	OC
Solid Tumour	MOMA-341-001	2 nd +	A Phase 1 Study of MOMA-341 as Monotherapy or Combination Therapy in Participants with Advanced or Metastatic Solid Tumors	EA	LM

Breast
 Gastrointestinal (GI)
 Lung
 Genitourinary (GU)
 Gynaecology
 Head & Neck
 Skin
 Neuro
 PH 1

Stream Contact Numbers

Breast – 0459 302 205
Gynaecological – 0491 299 561
GI – 0436 386 758
Lung – 0417 607 416
GU/neuro/Head & Neck/skin – 0436 387 664
Phase 1 – 0474 769 510

 Breast  Gastrointestinal (GI)  Lung  Genitourinary (GU)  Gynaecology  Head & Neck  Skin  Neuro  PH 1

List of Principal Investigators at Monash Health:

Associate Professor Zee Wan Wong (ZW)
Associate Professor Surein Arulananda (SA)
Associate Professor Peter Briggs (PB)
Associate Professor Marion Harris (MH)
Associate Professor David Pook (DP)
Associate Professor Andrew Strickland (AS)
Associate Professor Michelle White (MW)
Dr Elizabeth Ahern (EA)
Dr Muhammad Alamgeer (MA)
Dr Adithya Balasubramaniam (AB)
Dr Amy Body (AB)
Dr Daphne Day (DD)
Dr Sophia Frentzas (SF)
Dr Harriet Herbison (HH)
Dr Joshua Hurwitz (JH)
Dr Gwo Yaw Ho (GH)
Dr Elizabeth Liow (EL)
Dr Amelia McCartney (AM)
Dr Kate Webber (KW)
Dr Michael Mond (MM)